Lanean...
Therapeutic approaches to target alpha-synuclein pathology
Starting two decades ago with the discoveries of genetic links between alpha-synuclein and Parkinson’s disease risk and the identification of aggregated alpha-synuclein as the main protein constituent of Lewy pathology, alpha-synuclein has emerged as the major therapeutic target in Parkinson’s disea...
Gorde:
| Argitaratua izan da: | Exp Neurol |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6541231/ https://ncbi.nlm.nih.gov/pubmed/28987463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.expneurol.2017.10.003 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|